1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

340B Fight: Lilly ‘Disagrees’ With HHS Advisory Stating Discounts To Contract Pharmacies Are Required

 
• By Cathy Kelly

Lilly will not change its 340B discount restrictions in light of the advisory, which was released after HHS was sued by hospitals and other groups seeking a regulatory response against pharma actions.

Claims That Contract Pharmacies Aren't Passing Along Discounts To Patients

Eli Lilly and Company is maintaining that its actions to withhold 340B drug discounts from contract pharmacies for most of its products are legal, even though the US Health and Human Services Department said in a recent advisory opinion that manufacturers are required by law to offer discounted prices to contract pharmacies.

“We’ve reviewed HHS’s statement and we disagree with their conclusion,” the company told the Pink Sheet. “We continue to believe...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

More from Market Access

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

‘Brainless’ US MFN Policy Could Drive Pharma Investment To Europe

 
• By Francesca Bruce

European health systems already pay far too much for new medicines and payers will not accept higher prices to compensate for lower US prices, according to Anja Schiel, from NOMA, the Norwegian health technology assessment body.

Payment Cap Not Always Solution For Unaffordable Drugs, Maryland PDAB Director Says

 
• By Cathy Kelly

The state's Prescription Drug Affordability Board, the oldest of a growing list of the boards, chose six drugs for affordability reviews and has the authority to set a ceiling on the amount state and local government payers would reimburse for them.